QMS Perspective For Drug Device Combination

QMS for Drug-Device Combination Products: Complete Compliance Guide

A Quality Management System (QMS) for drug-device combination products ensures that products are consistently designed, manufactured, tested, and monitored in compliance with applicable regulations. Manufacturers typically implement ISO 13485, integrate risk management under ISO 14971, and comply with market-specific regulations such as FDA 21 CFR Part 4, FDA QMSR, and EU MDR (EU) 2017/745 to demonstrate product safety, quality, and regulatory compliance.

Speak with a Regulatory Expert Today

Introduction

The development of a drug-device combination product involves much more than combining a medicinal substance with a medical device. Manufacturers must establish a structured quality system that governs every stage of the product lifecycle—from design and development to manufacturing, distribution, post-market surveillance, and continuous improvement.

Unlike standalone pharmaceutical or medical device products, combination products often require compliance with multiple regulatory frameworks. This makes a robust Quality Management System (QMS) essential for maintaining consistent product quality while meeting the expectations of global regulatory authorities.

Whether the product is a prefilled syringe, auto-injector, infusion system, drug-eluting stent, or transdermal patch, the QMS provides the foundation for design controls, risk management, supplier qualification, document control, complaint handling, and regulatory compliance.

This guide explains how manufacturers can establish an effective QMS for drug-device combination products, the key regulatory standards involved, and the best practices for maintaining compliance throughout the product lifecycle.

Regulatory Snapshot

Aspect

Details

Primary Standard

ISO 13485

Risk Management

ISO 14971

United States

FDA QMSR & 21 CFR Part 4

European Union

EU MDR (EU) 2017/745

Purpose

Ensure quality, safety, and regulatory compliance throughout the product lifecycle

What Is a Quality Management System (QMS)?

A Quality Management System (QMS) is a structured framework of policies, procedures, processes, and records that ensures medical products are consistently designed, manufactured, controlled, and improved to meet regulatory and customer requirements.

For drug-device combination products, a QMS integrates quality practices across both pharmaceutical and medical device activities. It establishes controls for product development, manufacturing, supplier management, documentation, risk management, complaint handling, and post-market activities.

An effective QMS helps manufacturers:

  • Maintain consistent product quality
  • Demonstrate regulatory compliance
  • Improve operational efficiency
  • Reduce product defects
  • Support continuous improvement
  • Protect patient safety

Rather than being limited to manufacturing, the QMS should be implemented throughout the entire product lifecycle.

Which Standards Apply to Drug-Device Combination Products?

There is no single global quality standard dedicated exclusively to combination products. Instead, manufacturers typically implement a combination of internationally recognized standards and market-specific regulations.

ISO 13485 – Medical Device Quality Management

ISO 13485 is the internationally recognized standard for quality management systems used by medical device manufacturers. It establishes requirements for documenting processes, controlling product quality, managing suppliers, handling complaints, and maintaining regulatory compliance.

For drug-device combination products, ISO 13485 provides the framework for managing the medical device component while supporting regulatory expectations across multiple markets.

Key areas include:

  • Design and development controls
  • Document and record management
  • Supplier qualification
  • Production controls
  • Corrective and Preventive Actions (CAPA)
  • Internal audits
  • Complaint handling

FDA 21 CFR Part 4

In the United States, manufacturers of combination products must comply with 21 CFR Part 4, which clarifies how Current Good Manufacturing Practice (CGMP) requirements apply to products that combine drugs, devices, or biologics.

Rather than requiring manufacturers to implement every requirement from multiple regulatory frameworks, 21 CFR Part 4 identifies how pharmaceutical and medical device quality system requirements can be applied together in a practical manner.

This approach reduces unnecessary duplication while ensuring that both product components are appropriately controlled.

FDA QMSR

The FDA Quality Management System Regulation (QMSR) aligns the U.S. quality system requirements more closely with ISO 13485, creating greater consistency between international and U.S. regulatory expectations.

Manufacturers marketing combination products in the United States should ensure that their QMS supports both FDA requirements and internationally accepted quality management principles.

EU MDR (EU) 2017/745

Within the European Union, manufacturers must establish a quality system capable of supporting compliance with EU MDR (EU) 2017/745. The QMS should demonstrate that the medical device component consistently meets the applicable General Safety and Performance Requirements (GSPRs) throughout its lifecycle.

For integral drug-device combination products, the quality system also supports compliance with Article 117, where applicable.

ISO 14971 – Risk Management

Risk management is an integral part of every Quality Management System for combination products.

ISO 14971 provides a structured process for identifying hazards, evaluating risks, implementing risk control measures, and monitoring residual risks throughout the product lifecycle.

Rather than being a standalone activity, risk management should be integrated into design, manufacturing, validation, complaint handling, and post-market surveillance.

Also Read Risk Analysis of Drug-Device Combination Products.

Build a Compliant QMS for Your Drug-Device Combination Products

Operon Strategist helps manufacturers implement ISO 13485-compliant QMS and integrate risk management.

QMS Framework for Drug-Device Combination Products

QMS Element

Purpose

Standard / Regulation

Design Controls

Manage product development

ISO 13485 / FDA QMSR

Risk Management

Identify and control product risks

ISO 14971

Document Control

Maintain controlled records

ISO 13485

Supplier Management

Ensure supplier quality

ISO 13485

CAPA

Correct quality issues

ISO 13485 / FDA

Post-Market Surveillance

Monitor product performance

EU MDR

Expert Insight

Many manufacturers believe that implementing ISO 13485 alone is sufficient for combination products. In reality, a successful QMS integrates quality management with risk management, regulatory compliance, pharmaceutical quality practices, and product lifecycle controls. Building these elements into the system from the beginning is far more effective than adding them later to satisfy regulatory requirements.

Core Elements of a Quality Management System for Drug-Device Combination Products

An effective Quality Management System (QMS) is built on interconnected processes that ensure product quality, regulatory compliance, and continuous improvement throughout the product lifecycle. While the exact structure varies depending on the organization and target markets, the following elements are fundamental for manufacturers of drug-device combination products.

 

Design Controls

Design controls provide a structured framework for planning, developing, verifying, validating, and transferring products into production. They help ensure that the final product consistently meets user needs, intended use, and regulatory requirements.

A well-managed design control process typically includes:

  • Design planning
  • User needs and design inputs
  • Design outputs
  • Design reviews
  • Design verification
  • Design validation
  • Design transfer
  • Design changes
  • Design history documentation

For innovative combination products, robust design controls help demonstrate that both the drug and device components perform safely as an integrated system.

Explore Our Design History File (DHF) Service page.

 

Document and Record Control

Combination product manufacturers generate large volumes of documentation during product development and commercialization. A controlled document management system ensures that only approved versions of procedures, specifications, drawings, reports, and records are used throughout the organization.

Effective document control improves traceability, supports regulatory inspections, and reduces the risk of using outdated information.

Typical controlled documents include:

  • Standard Operating Procedures (SOPs)
  • Technical documentation
  • Risk Management Files
  • Validation reports
  • Manufacturing records
  • Training records
  • Change control documentation

     

Supplier Quality Management

Many combination products rely on external suppliers for active pharmaceutical ingredients, medical device components, packaging materials, and specialized manufacturing services. The manufacturer’s QMS should include procedures for selecting, qualifying, monitoring, and periodically evaluating suppliers.

Supplier management activities commonly include:

  • Supplier qualification
  • Supplier audits
  • Incoming material inspections
  • Performance monitoring
  • Supplier corrective actions
  • Quality agreements

Strong supplier controls help reduce variability and ensure consistent product quality throughout the supply chain.

 

Change Control

Every change to a combination product has the potential to affect safety, performance, or regulatory compliance. An effective change control process evaluates proposed modifications before implementation and documents their impact on product quality.

Examples of changes requiring assessment include:

  • Design modifications
  • Material substitutions
  • Software updates
  • Manufacturing process changes
  • Packaging revisions
  • Labeling updates

A formal change control process helps manufacturers maintain product consistency while ensuring compliance with applicable regulatory requirements.

 

Corrective and Preventive Actions (CAPA)

CAPA is one of the most important components of a Quality Management System. It provides a structured approach for investigating quality issues, identifying root causes, implementing corrective actions, and preventing recurrence.

An effective CAPA system enables organizations to:

  • Investigate product nonconformities
  • Analyze quality trends
  • Identify root causes
  • Implement corrective actions
  • Verify effectiveness
  • Promote continuous improvement

Rather than simply correcting isolated problems, CAPA strengthens the overall quality system by addressing systemic issues.

 

Validation and Process Control

Manufacturing processes should consistently produce products that meet predefined quality requirements. Validation demonstrates that critical processes operate reliably and repeatedly under controlled conditions.

Typical validation activities include:

  • Equipment qualification
  • Process validation
  • Cleaning validation
  • Software validation
  • Packaging validation
  • Sterilization validation (where applicable)

Process validation provides objective evidence that manufacturing activities remain under control throughout routine production.

 

Post-Market Surveillance (PMS)

Quality management does not end once a product reaches the market. Manufacturers must continuously monitor product performance to identify potential safety concerns and opportunities for improvement.

Post-market surveillance activities may include:

  • Complaint handling
  • Trend analysis
  • Adverse event reporting
  • Field safety corrective actions
  • Periodic product reviews
  • Customer feedback analysis

A proactive PMS system supports regulatory compliance while helping manufacturers maintain product quality over time.

Check Out our Global Product Registration Service Page.

Best Practices for Maintaining an Effective QMS

A Quality Management System should evolve with the organization and its products. Manufacturers can strengthen long-term compliance by adopting the following best practices:

  • Establish quality objectives aligned with business goals.
  • Maintain documentation throughout product development rather than preparing it retrospectively.
  • Integrate risk management into every stage of the product lifecycle.
  • Conduct regular internal audits to identify opportunities for improvement.
  • Provide ongoing training for employees involved in quality-related activities.
  • Periodically review supplier performance and quality agreements.
  • Monitor post-market data to drive continuous improvement.

How Operon Strategist Helps with QMS for Drug-Device Combination Products

Building and maintaining a compliant Quality Management System requires technical expertise, regulatory knowledge, and a structured implementation approach. Operon Strategist supports manufacturers in developing QMS frameworks that align with international standards and market-specific regulations.

Our services include:

Whether you are developing your first combination product or expanding into new global markets, our team helps establish quality systems that support sustainable regulatory compliance.

Ensure Seamless Regulatory Compliance for Your Device

Contact our regulatory experts to develop a QMS that supports successful product development and global market access.

FAQ's

A Quality Management System (QMS) is a structured framework of processes and procedures that ensures combination products are consistently designed, manufactured, controlled, and monitored in compliance with applicable regulatory requirements.

ISO 13485 is widely recognized as the international standard for medical device quality management. While regulatory requirements vary by market, implementing ISO 13485 helps manufacturers demonstrate compliance with medical device quality expectations.

FDA 21 CFR Part 4 defines how Current Good Manufacturing Practice (CGMP) requirements apply to combination products that include drug, device, or biologic components.

ISO 14971 provides the framework for risk management throughout the product lifecycle. Risk management should be integrated into the Quality Management System rather than treated as a separate activity.

Design controls ensure that combination products are developed systematically, verified, validated, and documented to meet user needs, regulatory requirements, and intended performance.

Corrective and Preventive Action (CAPA) is a quality process used to investigate issues, determine root causes, implement corrective actions, and prevent recurrence.

A QMS provides documented processes for product development, manufacturing, supplier management, complaint handling, and continuous improvement, enabling manufacturers to meet regulatory expectations across multiple markets.

A QMS should be implemented during the early stages of product development so that quality is built into the product lifecycle rather than added before regulatory submission.